Management of the rare entity of primary pancreatic cystic neoplasms

J Gastroenterol Hepatol. 2009 Jul;24(7):1203-10. doi: 10.1111/j.1440-1746.2009.05855.x. Epub 2009 May 10.

Abstract

Primary cystic neoplasms of the pancreas constitute a rare entity and are composed of a variety of neoplasms with a wide range of malignant potential. Approximately 90% of these lesions are serous cystic neoplasms or mucin-producing neoplasms. In contrast to serous cystadenomas which are nearly always benign, the mucinous cystic neoplasms represent a more diverse, heterogeneous spectrum of related neoplasms. Intraductal papillary mucinous neoplasms manifest a much greater latent or overt malignant potential than other cystic neoplasms of the pancreas. The various subgroups of cystic neoplasms of the pancreas are evaluated and compared through a review of current literature. No symptoms or signs are pathognomonic for the cystic pancreatic neoplasms. While identification of a cystic tumor is relatively easy, the identification of the specific tumor type may be difficult. Most investigators agree that accurate differentiation of benign from malignant neoplasms can be made only at histopathologic examination of the entire resected segment of the pancreas. Because of the low mortality and low postoperative morbidity, surgical resection is indicated in all patients with cystic tumors.

Publication types

  • Review

MeSH terms

  • Chemotherapy, Adjuvant
  • Cystadenoma / pathology
  • Cystadenoma / therapy
  • Diagnosis, Differential
  • Humans
  • Incidence
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Neoplasms, Cystic, Mucinous, and Serous / epidemiology
  • Neoplasms, Cystic, Mucinous, and Serous / pathology*
  • Neoplasms, Cystic, Mucinous, and Serous / therapy*
  • Pancreatectomy
  • Pancreatic Neoplasms / epidemiology
  • Pancreatic Neoplasms / pathology*
  • Pancreatic Neoplasms / therapy*
  • Pancreatic Pseudocyst / pathology
  • Patient Selection
  • Radiotherapy, Adjuvant
  • Treatment Outcome